Who is affected by this change?

This affects Blue Cross Blue Shield of North Dakota Oncology, Hematology, Endocrinology, OB-GYN providers in ND on Medicaid, Commercial plans.

When does this change take effect?

This change is effective Mar 1, 2026.

Which billing codes are affected?

The following codes are affected: C9308, C9307, J7299.

Back to dashboard

MedicaidPrior AuthMedium impact

Pharmacy Policy Updates

Blue Cross Blue Shield of North Dakota·ND · Oncology, Hematology, Endocrinology +1 more·Pharmacy

Effective date

Mar 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Blue Cross Blue Shield of North Dakota has updated multiple pharmacy policies with prior authorization changes for medical drugs effective March 1, 2026, and new billing codes effective January 1, 2026. The updates affect both Medicaid Expansion and Commercial plans, including new prior authorization requirements for oncology drugs and coding updates for hormone therapies.

Action Required

Action needed

By March 1, 2026: Billing team must update prior authorization protocols for Blenrep (belantamab mafodotin-blmf) and Itvisma (onasemnogene abeparvovec-brve) for Commercial patients. Update billing system with new codes C9308 (Kyxata), C9307 (Lynozyfic), and J7299 (Contraceptive Management) effective January 1, 2026. Review www.gatewaypa.com/policydisplay/52 and www.myprime.com for complete policy details after March 1, 2026.

Affected Billing Codes

C9308

C9307

J7299

Related policy hubs

Blue Cross Blue Shield of North Dakota policies ND policy changes Oncology Hematology Endocrinology OB-GYN Code C9308 Code C9307 Code J7299